Transdermal PTEN mRNA Delivery via HA-LNPs: A New Paradigm for Localized Cancer Immunotherapy

Study Background and Research Question

Melanoma remains one of the most aggressive skin cancers, characterized by its high metastatic potential and resistance to conventional therapies. Immune checkpoint inhibitors (ICIs) have reshaped treatment, but less than half of patients achieve durable responses due to tumor immune evasion and acquired resistance (source: paper). Loss or mutation of the tumor suppressor gene PTEN (phosphatase and tensin homolog) is widely implicated in melanoma and other malignancies, promoting unchecked cell proliferation via PI3K/Akt pathway activation and contributing to immune exclusion and poor ICI response. The central research question addressed by this study is whether restoring PTEN expression in melanoma using a localized, non-viral delivery system can reinvigorate antitumor immunity and suppress tumor growth, overcoming the limitations of previous gene therapy approaches (source: paper).

Key Innovation from the Reference Study

The primary innovation reported is the development of hyaluronate-conjugated lipid nanoparticles (HA-LNPs) that encapsulate PTEN mRNA for direct, non-invasive transdermal delivery. Unlike conventional lipid nanoparticles stabilized with poly(ethylene glycol) (PEG), which carry risks of immunogenicity and anaphylaxis, the HA-LNPs leverage an amphiphilic HA-dimyristoyl glycerol (HA-DMG) conjugate. This design enables HA to be stably embedded in the nanoparticle bilayer during self-assembly, providing colloidal stability, biocompatibility, and CD44-mediated tumor cell targeting (source: paper). The system is specifically tailored to deliver large mRNA payloads, such as PTEN mRNA, across the skin barrier and into tumor cells, thereby restoring tumor suppressor gene function at the site of disease.

Methods and Experimental Design Insights

The authors synthesized HA-DMG and incorporated it directly into the lipid mixture for nanoparticle self-assembly, replacing the need for post-formulation HA surface coating. This approach allowed for the one-step generation of HA-LNPs with high stability and uniformity. PTEN mRNA was encapsulated within the LNPs using established microfluidic mixing techniques, optimizing parameters for high encapsulation efficiency, minimal mRNA degradation, and suitable particle size for skin penetration (source: paper). The in vitro experiments assessed: - HA-LNP uptake by CD44-positive melanoma cell lines - Restoration of PTEN protein expression - Induction of immunogenic cell death (ICD) - Changes in cell viability and apoptosis In vivo, the efficacy and safety of the HA-LNP-PTEN mRNA system were evaluated in a murine melanoma model. Topical application of the formulation to the tumor site enabled analysis of skin and tumor penetration, PTEN protein restoration, immune cell infiltration, tumor growth inhibition, and systemic toxicity (source: paper).

Protocol Parameters

• mRNA payload size | ~1.5 kb | melanoma, other solid tumors | Matches full-length PTEN coding sequence; suitable for functional restoration | paper
• HA-LNP diameter | ~100 nm | transdermal delivery | Optimized for penetration through skin layers and tumor interstitium | paper
• HA-DMG content | ~5–10% of total lipid | LNP self-assembly | Balances colloidal stability and CD44 targeting efficacy | paper
• Topical dose frequency | once daily for 1–2 weeks | murine tumor model | Sufficient for sustained PTEN expression and tumor growth inhibition | paper
• Storage of mRNA-LNP | -80°C (recommended) | all mRNA therapeutics | Maintains mRNA and nanoparticle integrity | workflow_recommendation
• RNase-free handling | always | all mRNA applications | Prevents degradation of mRNA cargo during preparation and application | workflow_recommendation

Core Findings and Why They Matter

The HA-LNP system achieved efficient encapsulation and delivery of PTEN mRNA, leading to significant biological effects both in vitro and in vivo (source: paper):

• Efficient tumor targeting: HA-LNPs displayed superior uptake by CD44-expressing melanoma cells compared to PEG-LNPs, attributed to HA-CD44 receptor interactions.
• PTEN restoration: Delivered mRNA was translated into functional PTEN protein, reversing the loss typical of advanced melanoma.
• Immunogenic cell death induction: Treated tumor cells exhibited hallmarks of ICD, including calreticulin exposure and HMGB1 release, which are known to activate dendritic cells and promote antitumor T cell responses.
• In vivo antitumor efficacy: Topically applied HA-LNP-PTEN mRNA penetrated deeply into tumor tissue, significantly suppressed tumor growth, and enhanced local immune activation without detectable systemic toxicity.

These results collectively demonstrate the clinical potential of localized, mRNA-based immunotherapy for melanoma, with the possibility of sensitizing tumors to ICIs and overcoming resistance mechanisms linked to PTEN loss.

Comparison with Existing Internal Articles

Several internal resources explore the utility of mRNA-based PTEN restoration for cancer research and gene therapy. For example, the article "EZ Cap™ Human PTEN mRNA: Enhancing Cancer Research and Gene Therapy" discusses how tumor suppressor gene mRNA with advanced modifications—such as Cap 1 structure and poly(A) tail—delivers superior stability and translational efficiency, which aligns with the requirements for nanoparticle-mediated delivery platforms. The present study extends these mechanistic insights by validating a clinically relevant, non-invasive route (transdermal) and a targeted delivery approach (HA-LNPs), thus bridging the gap between in vitro workflow advantages and in vivo translational potential. Additionally, "EZ Cap™ Human PTEN mRNA: Transforming Tumor Suppressor De..." provides a mechanistic overview of how transient mRNA delivery can precisely restore gene function without genomic integration risks, complementing the safety advantages highlighted in the reference study.

Limitations and Transferability

Despite its promising findings, the study is subject to several limitations. The use of murine melanoma models, while informative, may not fully recapitulate the complexity of human skin architecture, tumor microenvironment, or immunological responses. Long-term safety, durability of PTEN expression, and potential for immune sensitization require further validation in larger, more diverse preclinical models and eventual clinical trials. Moreover, while HA-LNPs offer a compelling alternative to PEG-LNPs in terms of biocompatibility and targeting, their scalability and regulatory acceptance for clinical manufacturing remain areas for development (source: paper). Nonetheless, the principles demonstrated—transient, non-integrating mRNA delivery, CD44-mediated targeting, and the avoidance of PEG-related immune risks—are transferrable to other skin cancers and potentially to localized immunotherapy applications in other tissues, pending further study.

Research Support Resources

To implement similar mRNA transfection and expression workflows, researchers may require access to high-quality, translationally optimized mRNA reagents. The EZ Cap™ Human PTEN mRNA (SKU R1025) from APExBIO is an in vitro transcribed PTEN mRNA featuring a Cap 1 structure and poly(A) tail, closely mimicking endogenous eukaryotic mRNA to enhance stability and translation in delivery contexts such as LNPs or direct transfection (source: product_spec). Following best practices for RNase-free handling, proper storage, and optimized formulation with nanoparticle carriers can help researchers replicate or extend the findings of this study in their own cancer research or gene therapy investigations.